Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-086-5 | CAS number: 132-98-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
Penicillin V (CAS Number 87-08-1, also known as Penicillin V potassium, Penicillin VK, Phenoxymethyl penicillin, Phenoxymethylpenicillin Benzathine) is indicated for the treatment of mild to moderately severe infections due to penicillin sensitive microorganisms. Penicillin V acts through the inhibition of biosynthesis of bacterial cell-wall mucopeptide. The doses and duration of treatment depends on microorganism and product formulation. Penicillins belong to the beta-lactam antibiotics.
Penicillin V has been used since many decades in patients. Penicillin antibiotics are in general substances with low toxicity. The most often described effects in humans are gastrointestinal, demonstrated in mouse and rat. Penicillin V is generally well-tolerated in humans. The hazard characterisation of penicillin and derivatives in humans can be deduced from the available long-term studies in the literature. A review of the safety profile of long-term penicillin therapy revealed some cases of adverse effects such as transient nausea, diarrhea, and allergic reactions - albeit these adverse effects are consistent with the known adverse event profile of penicillin. There was no report of an increase in adverse drug reactions involving long-term administration of penicillin in these studies. Therefore, given that Penicillin has an extensive history of safe use, and the lack of any serious adverse events in these studies supports its status as a safe drug. Additionally, the European Medicines Agency (EMA) Committee for veterinary medicinal products (CVMP) has assessed Phenoxymethylpenicillin, and the CVMP concluded that phenoxymethylpenicillin is rapidly metabolised and excreted, and has minimal direct toxicity to humans or animals. They noted that the therapeutic index of penicillin is more than 100 and that any toxic effects of non-allergic nature have only been reported after extremely high doses.
Carcinogenesis studies of Penicillin VK, was performed in F344/N rats and B6C3F, mice. In this study penicillin VK was administered to rats and mice at doses of 0, 500, or 1000 mg/kg. Drug was administered by oral gavage in corn oil. Toxic lesions of the stomach were seen in mice after ampicillin trihydrate administration and in mice after penicillin VK administration. There was no evidence for carcinogenic activity in rats and mice after penicillin VK administration.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1987
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Two-years study design. Groups of 50 rats and 50 mice of each sex received penicillin VK in corn oil by gavage 5 days for 103-104 weeks. Rats received 0, 500, or 1000 mg/kg penicillin VK. Mice 0, 500, or 1000 mg/kg penicillin VK. The control groups received corn oil alone. At the conclusion of the 2-year dosing period, animals were kept for 1 to 2 weeks of observation without dosing and killed by carbon dioxide inhalation. Necropsy was performed on all animals. ods (Cox, 1972). Differences in survival were analyzed by life-table methods (Cox, 1972).
- GLP compliance:
- not specified
- Specific details on test material used for the study:
- USP grade lots C9014 and H1688
- Species:
- other: Rodents : Male and female F344/N rats and B6CF3 mice obtained from Charles River Breeding Laboratories (portage, MI)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Rodents were placed on study at 7-8 weeks of age. Animals were assigned to groups using a table of random numbers and were housed by sex, five
per cage, in polycarbonate cagescovered with fiber filters and were provided with heat-treated hardwood chips as bedding (Ancare Corp., L.I., NY). Tap water and NIH 07 feed (Zeigler Bros, Gardners, PA) were provided ad libitum. The animals were maintained in a room that was kept at 66-81°F [19 - 27 °C] with 10- 12 air changes per hour, and a 12-hr fluorescent light cycle. All animals were checked daily for clinical signs and moribund animals were necropsied. Animal body weights were taken once a week during the first 13 weeks of study and thereafter every 4 weeks. - Route of administration:
- oral: feed
- Vehicle:
- corn oil
- Details on exposure:
- Rodents were placed on study at 7-8 weeks of age. Animals were assigned to groups using a table of random numbers and were housed by sex, five
per cage, in polycarbonate cagescovered with fiber filters and were provided with heat-treated hardwood chips as bedding (Ancare Corp., L.I., NY). Tap water and NIH 07 feed (Zeigler Bros, Gardners, PA) were provided ad libitum. The animals were maintained in a room that was kept at 66-81°F [19 - 27 °C] with 10- 12 air changes per hour, and a 12-hr fluorescent light cycle. All animals were checked daily for clinical signs and moribund animals were necropsied. Animal body weights were taken once a week during the first 13 weeks of study and thereafter every 4 weeks. - Analytical verification of doses or concentrations:
- yes
- Remarks:
- Dose solutions were checked throughout the course of the study and were within ± 10% of the targeted concentrations (Dunnick, 1987, 1988).
- Duration of treatment / exposure:
- 103-104 weeks
- Frequency of treatment:
- Daily once. 5 days weekly
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- Groups of 50 rats and 50 mice of each sex received Penicillin VK in corn oil.
- Control animals:
- yes, concurrent no treatment
- Positive control:
- no
- Observations and examinations performed and frequency:
- All animals were checked daily for clinical signs and moribund animals were necropsied. Animal body weights were taken once a week during the first 13 weeks of study and thereafter every 4 weeks.
- Sacrifice and pathology:
- Necropsy was performed on all animals. Tissues were preserved in 10% neutral buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. The following tissues were examined microscopically: grossly observed tissue masses,mandibular, or mesenteric lymph nodes; salivary glands;
bone including marrow;
thyroid gland, parathyroids;
small intestine;
large intestine;
liver;
prostate/testes/epididymis or ovaries/uterus;
lungs with mainstem bronchi;
skin;
heart;
esophagus;
stomach;
brain;
thymus;
trachea;
pancreas;
spleen;
kidneys;
adrenal glands;
urinary bladder;
pituitary gland;
eyes (if gross lesions were evident);
and mammary glands. - Statistics:
- Differences in survival were analyzed by life-table methods (Cox, 1972). For the analysis of tumor incidence data, survival-adjusted procedures were used to assessdose-response trends and to make pairwise comparisons between dosed groups and controls (Haseman, 1984). Fisher exact tests and Cochran rmitage trend tests were also utilized to assesstumor incidence data. Results are considered as significant where the p value is ~0.05.
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Clinical signs were observed sporadically and included diarrhea in rats and male
mice dosed with penicillin. - Dermal irritation (if dermal study):
- not specified
- Mortality:
- no mortality observed
- Description (incidence):
- Survival in all groups of rats was 50% or greater until Week 92. Survival of
mice dosed with penicillin VK was comparable to vehicle controls. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Mean body weights of male and female rats receiving penicillin VK were similar to the corresponding vehicle control groups. Mean body weights of male mice receiving penicillin VK were comparable to controls, but mean body weights of dosed female mice were 4- 16% lower than those of the vehicle controls from Week 28 to the end of the study.
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Nonneoplastic lesions of the glandular stomach were seen in dosed male
and female mice, and lesions of the gallbladder were seen in male mice. The incidence of hepatocellular adenomas was decreased in high-dose male mice (14/50, 15/49,4/49). - Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- No compound-related increases in neoplasms were seen in male or female rats or mice.
- Key result
- Dose descriptor:
- dose level:
- Effect level:
- > 500 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- Conclusions:
- There is no evidence of carcinogenicity in rats or mice after penicillin VK dosing. Short-term genetic toxicity test results with ampicillin trihydrate and penicillin V and VK indicate that these drugs are not genotoxic (Dunnick, 1987, 1988). he most common side effects reported in humans after penicillin tratment are hypersensitivity (anaphylactoid reactions). Gastrointestinal toxicity was seen in mice after penicillin V Potassium amministration and this target organ toxicity is similar to what has been observed in humans.
- Executive summary:
Toxicology and carcinogenesis studies of ampicillin trihydrate and penicillin VK, two widely used β-lactam antibiotics, were performed in F344/N rats and B6C3F, mice. In these studies ampicillin trihydrate was administered for 2 years to rats at doses of 0, 750, or 1500 mg/kg and to mice at doses of 0, 1500, or 3000 mg/kg, and penicillin VK was administered to rats and mice at doses of 0, 500, or 1000 mg/kg. Both drugs were administered
by oral gavage in corn oil. Toxic lesions of the stomach were seen in rats and mice after ampicillin trihydrate administration and in mice after penicillin VK administration. There was no evidence for
carcinogenic activity in female rats or male and female mice after ampicillin trihydrate administration or in rats and mice after penicillin VK administration.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- Study duration:
- chronic
- Species:
- other: rodents
Justification for classification or non-classification
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.